n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with cilengitide in 2 studies
Studies (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Trials (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Recent Studies (post-2010) (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) |
---|---|---|---|---|---|
18 | 5 | 13 | 194 | 29 | 133 |
Protein | Taxonomy | n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide (IC50) | cilengitide (IC50) |
---|---|---|---|
Integrin beta-3 | Homo sapiens (human) | 0.3087 | |
Integrin beta-1 | Homo sapiens (human) | 1.0131 | |
Integrin alpha-V | Homo sapiens (human) | 0.514 | |
Integrin alpha-IIb | Homo sapiens (human) | 2.399 | |
Integrin alpha-5 | Homo sapiens (human) | 0.9006 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Integrin beta-5 | Homo sapiens (human) | 0.4791 | |
Integrin beta-6 | Homo sapiens (human) | 4.042 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0005 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tucker, GC | 1 |
Colombo, L; Paolillo, M; Russo, MA; Schinelli, S; Serra, M | 1 |
2 review(s) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and cilengitide
Article | Year |
---|---|
Integrins: molecular targets in cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Indoles; Integrins; Melanoma; Neoplasms; Porphyrins; Skin Neoplasms; Snake Venoms; Sulfonamides | 2006 |
Small molecule integrin antagonists in cancer therapy.
Topics: Anoikis; Humans; Indoles; Integrin alphaVbeta3; Integrins; Neoplasms; Peptides; Receptors, Vitronectin; Signal Transduction; Snake Venoms; Sulfonamides | 2009 |